XML 109 R94.htm IDEA: XBRL DOCUMENT v3.24.2
Segment Information - Summary of Net Sales by Segment and Geographical Area (Details)
€ in Millions
 6 Months Ended 12 Months Ended
Jun. 30, 2024
EUR (€)
segment
Jun. 30, 2023
EUR (€)
Dec. 31, 2023
EUR (€)
Disclosure of geographical areas [line items]      
Net sales € 21,209 € 20,187 € 43,070
Number of operating segments | segment 2    
Other revenues € 1,289 1,358 3,374
Cost of sales (6,849) (6,347) (14,236)
Research and development expense (3,423) (3,193) (6,728)
Selling, general and administrative expense (5,260) (5,182) (10,692)
Attributable to non-controlling interests 17 26 36
Dupixent      
Disclosure of geographical areas [line items]      
Net sales 18,378 17,467 37,890
Business operating income 4,931 5,220 11,247
Other revenues 1,257 1,331 3,322
Cost of sales (5,756) (5,388) (12,282)
Research and development expense (3,331) (3,082) (6,509)
Selling, general and administrative expense (4,260) (4,248) (8,868)
Other operating income and expenses (1,417) (897) (2,387)
Share of profit/(loss) from investments accounted for using the equity method 66 48 101
Attributable to non-controlling interests (6) (11) (20)
Dupixent | Pharma Segment      
Disclosure of geographical areas [line items]      
Net sales 16,059 15,077  
Dupixent | Pharma Launches      
Disclosure of geographical areas [line items]      
Net sales 1,295 715  
Dupixent | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 6,138 4,878  
Dupixent | Total Vaccines      
Disclosure of geographical areas [line items]      
Net sales 2,319 2,390  
Dupixent | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 1,348 1,428  
Dupixent | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 188 162  
Dupixent | Nexviazyme      
Disclosure of geographical areas [line items]      
Net sales 320 184  
Dupixent | Sarclisa      
Disclosure of geographical areas [line items]      
Net sales 227 181  
Dupixent | Altuviiio      
Disclosure of geographical areas [line items]      
Net sales 280 19  
Dupixent | Rezurock      
Disclosure of geographical areas [line items]      
Net sales 207 141  
Dupixent | Cablivi      
Disclosure of geographical areas [line items]      
Net sales 113 113  
Dupixent | Xenpozyme      
Disclosure of geographical areas [line items]      
Net sales 72 38  
Dupixent | Enjaymo      
Disclosure of geographical areas [line items]      
Net sales 55 33  
Dupixent | Tzield      
Disclosure of geographical areas [line items]      
Net sales 21 6  
Dupixent | RSV Vaccines      
Disclosure of geographical areas [line items]      
Net sales 200 0  
Dupixent | Meningitis Travel And Endemic Vaccines      
Disclosure of geographical areas [line items]      
Net sales 582 569  
Opella      
Disclosure of geographical areas [line items]      
Net sales 2,831 2,720 5,180
Business operating income 739 850 1,438
Other revenues 32 27 52
Cost of sales (1,077) (949) (1,933)
Research and development expense (92) (111) (219)
Selling, general and administrative expense (1,002) (936) (1,828)
Other operating income and expenses 43 100 181
Share of profit/(loss) from investments accounted for using the equity method 9 7 21
Attributable to non-controlling interests (5) (8) (16)
Opella | Seasonal Symptoms And Pain Relief      
Disclosure of geographical areas [line items]      
Net sales 1,216 1,261  
Opella | Wellness Brands      
Disclosure of geographical areas [line items]      
Net sales 1,258 1,112  
Opella | Others      
Disclosure of geographical areas [line items]      
Net sales 357 347  
Other segment      
Disclosure of geographical areas [line items]      
Net sales 0 [1] 0 [2] 0 [3]
Business operating income (14) [1] (11) [2] (15) [3]
Other revenues 0 [1] 0 [2] 0 [3]
Cost of sales 3 [1] (5) [2] (1) [3]
Research and development expense 0 [1] 0 [2] 0 [3]
Selling, general and administrative expense 2 [1] 2 [2] 4 [3]
Other operating income and expenses (19) [1] (8) [2] (18) [3]
Share of profit/(loss) from investments accounted for using the equity method 0 [1] 0 [2] 0 [3]
Attributable to non-controlling interests 0 [1] 0 [2] 0 [3]
Other Products Segment | Other Products Segment      
Disclosure of geographical areas [line items]      
Net sales 8,626 9,484  
Other Products Segment | of which      
Disclosure of geographical areas [line items]      
Net sales 278 280  
Europe      
Disclosure of geographical areas [line items]      
Net sales 4,882 5,034 10,392
Europe | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 4,074 4,194  
Europe | Dupixent | Pharma Segment      
Disclosure of geographical areas [line items]      
Net sales 3,692 3,624  
Europe | Dupixent | Pharma Launches      
Disclosure of geographical areas [line items]      
Net sales 249 168  
Europe | Dupixent | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 770 587  
Europe | Dupixent | Total Vaccines      
Disclosure of geographical areas [line items]      
Net sales 382 570  
Europe | Dupixent | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 248 231  
Europe | Dupixent | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 30 37  
Europe | Dupixent | Nexviazyme      
Disclosure of geographical areas [line items]      
Net sales 95 42  
Europe | Dupixent | Sarclisa      
Disclosure of geographical areas [line items]      
Net sales 64 56  
Europe | Dupixent | Altuviiio      
Disclosure of geographical areas [line items]      
Net sales 0 0  
Europe | Dupixent | Rezurock      
Disclosure of geographical areas [line items]      
Net sales 12 2  
Europe | Dupixent | Cablivi      
Disclosure of geographical areas [line items]      
Net sales 43 49  
Europe | Dupixent | Xenpozyme      
Disclosure of geographical areas [line items]      
Net sales 24 15  
Europe | Dupixent | Enjaymo      
Disclosure of geographical areas [line items]      
Net sales 10 4  
Europe | Dupixent | Tzield      
Disclosure of geographical areas [line items]      
Net sales 1 0  
Europe | Dupixent | RSV Vaccines      
Disclosure of geographical areas [line items]      
Net sales 7 0  
Europe | Dupixent | Meningitis Travel And Endemic Vaccines      
Disclosure of geographical areas [line items]      
Net sales 97 72  
Europe | Opella      
Disclosure of geographical areas [line items]      
Net sales 808 840  
Europe | Other Products Segment | Other Products Segment      
Disclosure of geographical areas [line items]      
Net sales 2,673 2,869  
Europe | Other Products Segment | of which      
Disclosure of geographical areas [line items]      
Net sales 274 264  
United States      
Disclosure of geographical areas [line items]      
Net sales 9,067 7,988 € 18,512
United States | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 8,294 7,366  
United States | Dupixent | Pharma Segment      
Disclosure of geographical areas [line items]      
Net sales 7,550 6,709  
United States | Dupixent | Pharma Launches      
Disclosure of geographical areas [line items]      
Net sales 868 460  
United States | Dupixent | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 4,437 3,682  
United States | Dupixent | Total Vaccines      
Disclosure of geographical areas [line items]      
Net sales 744 657  
United States | Dupixent | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 311 347  
United States | Dupixent | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 16 19  
United States | Dupixent | Nexviazyme      
Disclosure of geographical areas [line items]      
Net sales 174 123  
United States | Dupixent | Sarclisa      
Disclosure of geographical areas [line items]      
Net sales 100 76  
United States | Dupixent | Altuviiio      
Disclosure of geographical areas [line items]      
Net sales 259 17  
United States | Dupixent | Rezurock      
Disclosure of geographical areas [line items]      
Net sales 188 140  
United States | Dupixent | Cablivi      
Disclosure of geographical areas [line items]      
Net sales 60 58  
United States | Dupixent | Xenpozyme      
Disclosure of geographical areas [line items]      
Net sales 37 21  
United States | Dupixent | Enjaymo      
Disclosure of geographical areas [line items]      
Net sales 30 19  
United States | Dupixent | Tzield      
Disclosure of geographical areas [line items]      
Net sales 20 6  
United States | Dupixent | RSV Vaccines      
Disclosure of geographical areas [line items]      
Net sales 116 0  
United States | Dupixent | Meningitis Travel And Endemic Vaccines      
Disclosure of geographical areas [line items]      
Net sales 301 291  
United States | Opella      
Disclosure of geographical areas [line items]      
Net sales 773 622  
United States | Other Products Segment | Other Products Segment      
Disclosure of geographical areas [line items]      
Net sales 2,245 2,567  
United States | Other Products Segment | of which      
Disclosure of geographical areas [line items]      
Net sales 3 3  
Other countries      
Disclosure of geographical areas [line items]      
Net sales 7,260 7,165  
Other countries | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 6,010 5,907  
Other countries | Dupixent | Pharma Segment      
Disclosure of geographical areas [line items]      
Net sales 4,817 4,744  
Other countries | Dupixent | Pharma Launches      
Disclosure of geographical areas [line items]      
Net sales 178 87  
Other countries | Dupixent | Dupixent      
Disclosure of geographical areas [line items]      
Net sales 931 609  
Other countries | Dupixent | Total Vaccines      
Disclosure of geographical areas [line items]      
Net sales 1,193 1,163  
Other countries | Dupixent | Polio/Pertussis/ Hib Vaccines      
Disclosure of geographical areas [line items]      
Net sales 789 850  
Other countries | Dupixent | Influenza Vaccines      
Disclosure of geographical areas [line items]      
Net sales 142 106  
Other countries | Dupixent | Nexviazyme      
Disclosure of geographical areas [line items]      
Net sales 51 19  
Other countries | Dupixent | Sarclisa      
Disclosure of geographical areas [line items]      
Net sales 63 49  
Other countries | Dupixent | Altuviiio      
Disclosure of geographical areas [line items]      
Net sales 21 2  
Other countries | Dupixent | Rezurock      
Disclosure of geographical areas [line items]      
Net sales 7 (1)  
Other countries | Dupixent | Cablivi      
Disclosure of geographical areas [line items]      
Net sales 10 6  
Other countries | Dupixent | Xenpozyme      
Disclosure of geographical areas [line items]      
Net sales 11 2  
Other countries | Dupixent | Enjaymo      
Disclosure of geographical areas [line items]      
Net sales 15 10  
Other countries | Dupixent | Tzield      
Disclosure of geographical areas [line items]      
Net sales   0  
Other countries | Dupixent | RSV Vaccines      
Disclosure of geographical areas [line items]      
Net sales 77 0  
Other countries | Dupixent | Meningitis Travel And Endemic Vaccines      
Disclosure of geographical areas [line items]      
Net sales 184 206  
Other countries | Opella      
Disclosure of geographical areas [line items]      
Net sales 1,250 1,258  
Other countries | Other Products Segment | Other Products Segment      
Disclosure of geographical areas [line items]      
Net sales 3,708 4,048  
Other countries | Other Products Segment | of which      
Disclosure of geographical areas [line items]      
Net sales € 1 € 13  
[1]
(a)     The “Other” column reconciles segmental results to the total per the consolidated financial statements.
[2]
(a)    The “Other” column reconciles segmental results to the total per the consolidated financial statements.
[3]
(a)    The “Other” column reconciles segmental results to the total per the consolidated financial statements.